First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE ® 327 (R327), resulting in high peak urine concentrations, as ...
SYDNEY, June 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed ...
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) managing director and CEO James Graham talks with Proactive’s Jonathan Jackson about how Recce has administered the first doses in the latest cohort of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results